Ifinatamab deruxtecan

The IDeate-Esophageal01 Phase 3 trial has begun evaluating ifinatamab deruxtecan, a potential first-in-class B7-H3 directed antibody-drug conjugate, against standard chemotherapy in advanced esophageal squamous cell carcinoma.

Small cell lung cancer affects approximately 400,000 new patients globally, with Asia reporting the highest case numbers, followed by Europe and North America.

Perioperative nivolumab demonstrates superior event-free survival compared to neoadjuvant nivolumab in resectable NSCLC, showing benefit even in PD-L1 negative cases.

Ifinatamab deruxtecan (I-DXd) demonstrated promising activity in patients with extensive-stage small cell lung cancer (ES-SCLC) at the World Congress on Lung Cancer.

Interim data from the IDeate-Lung01 trial reveal a 54.8% objective response rate with ifinatamab deruxtecan (I-DXd) at 12 mg/kg in patients with extensive-stage small cell lung cancer (ES-SCLC).